30 closest matches · ranked by relevance
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Multiple Myeloma
Primary: Number of Participants Achieving a Complete Response — 51 Participants
Multiple Myeloma
Primary: Number of Multiple Myeloma (MM) Participants Categorized by Clinical Characteristics — 342; 366; 48; 36 Participants
Multiple Myeloma · Myeloma · Disability Physical
Primary: Intervention Attendance (Feasibility) — 50 percentage of participants
Multiple Myeloma · Smoldering Multiple Myeloma · Monoclonal Gammopathy of Undetermined Significance
Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants
Smoldering Multiple Myeloma
Primary: Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases. — 0 proportion of participants
Multiple Myeloma
Primary: Percentage of Participants With 1-year Response Rate of CR/sCR — 52.9; 50.0 percentage of participants — p=0.3657
Multiple Myeloma
Primary: Immune Response — 7 Particpants
Multiple Myeloma
Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…
Myeloma-Multiple · Myeloma, Plasma-Cell
Primary: Number of Participants That Had Any Grade ≤2, and 3, 4 and 5 Adverse Events Following Administration of T Cells Expressing Anti- Signaling Lymphocytic Activation…
Multiple Myeloma
Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Event-free Survival — 29 percentage of participants
Multiple Myeloma
Primary: Number of Participants With Adverse Events (AEs) — 6 Participants
Multiple Myeloma
Primary: The Number of Participants With a Significant Increase in Serum Creatinine at 12 Months — 17; 13 Participants
Multiple Myeloma
Primary: Percentage of Patients With an Objective Response — 31 percentage of patients
Relapsed or Plateau-Phase Multiple Myeloma
Primary: Complete Response or Partial Response Based on M-Protein Assessments Only — 0; 0 Participants
Multiple Myeloma
Primary: Overall Response Rate (ORR) by Independent Review Committee (IRC) (Full Analysis Population) — 31; 34; 48 Percentage of Participants
Refractory Multiple Myeloma · Stage I Multiple Myeloma · Stage II Multiple Myeloma
Primary: The Number of Confirmed Responses (Complete Response [CR], Very Good Partial Response [VGPR], or Partial Response [PR]) — 0 participants
Multiple Myeloma
Primary: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Multiple Myeloma
Primary: Progression Free Survival (PFS) — 6.6; 7.5; 7.6 months
Multiple Myeloma and Plasma Cell Neoplasm
Primary: The Number of Confirmed Hematologic Responses (Complete, Partial, or Very Good Partial Response) — 39; 11; 9; 10 participants
ISS Stage I Plasma Cell Myeloma · ISS Stage II Plasma Cell Myeloma · ISS Stage III Plasma Cell Myeloma
Primary: Number of Participants With Adverse Events — 8 Participants
Multiple Myeloma
Primary: Therapeutic Efficacy — 1 Participants
Multiple Myeloma
Primary: Number of Participants With Pulmonary Toxicity — 32 Participants
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — 20 mg LBH589
Multiple Myeloma
Primary: Bone Formation Markers Measurement — 21.87; 23.2; 1.33; 28.75 U/L — p=0.002
Multiple Myeloma
Primary: Objective Response Rate — 6; 16; 11; 10 Participants
Smoldering Multiple Myeloma
Primary: 2 Year Progression Free Percent — 62.5 percentage of participants
Multiple Myeloma
Primary: Fraction of Patients (n=3) for Whom a sdAb Could be Generated That Binds to the Idiotype of the Paraprotein. — 2 Participants
Multiple Myeloma
Primary: Response Rates by Blade Criteria — 2; 5; 3; 2 Participants